Archives of Medicine

  • ISSN: 1989-5216
  • Journal h-index: 17
  • Journal CiteScore: 4.25
  • Journal Impact Factor: 3.58
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Review Article - (2023) Volume 15, Issue 5

Viability of durvadya taila and manjisthadi kwatha for youngsters' dermatitis: A review

Varashree Suryakanth*
Department of Biochemistry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, India
*Correspondence: Varashree Suryakanth, Department of Biochemistry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, India, Email:

Received: 15-Aug-2023, Manuscript No. ipaom-23-14120; Editor assigned: 17-Aug-2023, Pre QC No. P-14120; Reviewed: 02-Sep-2023, QC No. Q-14120; Revised: 08-Sep-2023, Manuscript No. R-14120; Published: 15-Sep-2023


Ayurvedic pediatric OPDs much of the time face the Kshudra kustha sort of Vicharchika, which is set apart by the side effects Kandu (tingling), Srava (release), Pidaka (vesicles) and Shyava Varna (staining). Dermatitis sores that are dry and blackish are brought about by Vata contribution, though tingling in the tormented locales is brought about by Kapha and Srava by Pitta. Skin inflammation and Vicharchika are more comparable than not. Shodhana and Shamana treatment are stressed in the conventional texts of Ayurveda as a line of treatment at different places in the administration of Kustha. Shamana treatment is best over Shodhana treatment in young people. To evaluate the viability of Durvadya Taila and Laghu Manjisthadi Kwatha in Vicharchika in kids matured 5 to 16 years, a clinical exploration was carried out utilizing both comprehensive and elite measures. Patients got LaghuManjisthadi Kwatha two times day to day for 45 days while likewise getting outer use of Durvadya Taila and they were reached for follow-up care following 15 days of treatment finish. In a gathering of 30 patients, most of patients (86.67%) had extensive improvement, 6.7% had total reduction and 6.67% had gentle improvement. Durvadya Taila and Laghu Manjisthadi Kwatha are clearly protected and successful in the administration of Vicharchika in kids, as per the clinical examination.


Vicharchika; Eczema; Kustha; Durvadya Taila; Laghu Manjisthadi Kwatha


Vicharchika; Eczema; Kustha; Durvadya Taila; Laghu Manjisthadi Kwatha


The skin, the most noticeable organ of the body, plays a critical part in physical, social and mental correspondence. It likewise incredibly impacts how we appear. The development of skin issues hinders the capability of the skin. Pediatricians treat patients with dermatological issues consistently, making up around 25% of a bustling short term practice. All types of skin conditions have been canvassed in Ayurveda under the umbrella term Kustha, which is additionally separated into Maha Kustha and Kshudra Kustha. One of the Kshudra Kustha is Vicharchika. Vicharchika is a skin condition where emissions across the skin arise with dull pigmentation, tingling and bountiful release from the injury, as per Acharya Charaka.

Literature Review


As indicated by Acharya Sushruta, Vicharchika is described by extraordinary tingling, extreme inconvenience and dryness. As indicated by Acharya Kashyapa, Vicharchika is the presence of dark, red ulcers with agony, releases and festering across the skin. Skin inflammation and vicharchika are practically identical. Skin aggravation known as dermatitis isn't transmittable and is portrayed by erythema, scaling, edema, vesiculation and spilling. Skin inflammation, generally known as atopic dermatitis, is portrayed by skin aggravation. Patches of skin that are textured or hard, now and again joined by redness, rankling and tingling, are the primary side effects of the issue. The most common intermittent skin condition that influences youngsters and newborn children is dermatitis [1]. The seven significant elements that have an impact in the pathophysiology of this skin sickness are the three vitiated doshas of vata, pitta and kapha, as well as weakened tvak, rakta, mamsa and ambu. Kapha is the major dosha embroiled in Vicharchika. Most Vicharchika (Skin inflammation) patients who don't answer well to customary clinical treatment look for Ayurvedic treatment with high any expectations of being restored of their condition.

Laghu Manjisthadi Kwatha

Eight unique drugs make up Laghu Manjisthadi Kwatha. The essential dosha engaged with the pathophysiology of Vicharchika, Kaphapittahara, is one of the Tridoshahara characteristics shared by every one of the fundamental parts of this kwatha. A sickness with a Kapha transcendence is vicharchika. In this definition, Tikta, Kashaya rasa, Laghu, Rukshaguna, Ushna virya and Katuvipaka make up most of the drugs. These medication related characteristics help in lessening kapha and pittadosha. All prescriptions joined with the characteristics of Kustaghana, Kandughana, Krimighna, Rasayana, as well as Varnya, Lekhana and Dahaprashamana [2].

Most of endorsed yoga drugs contain Tiktarasa, which further develops Agni and helps in Srotoshuddhi by tending to Amashaya and Amacondition. These prescriptions have raktashodhaka and raktaprasadana qualities because of the strength of tikta and kashayarasa. These characteristics straightforwardly benefit Kandu, Daha, Vaivarnata, Pidika and Srava as rakta is one of the essential dushya in Tvak vikara. Manjistha and Daruharidra's Raktasodhaka and Vranashodhana attributes display Kustaghana action and help in the mending of wounds. It has been exhibited that these prescriptions have an injury recuperating impact. The harithaki's srotoshodhaka property advances solid blood stream, takes care of the tissues and makes an enemy of hypersensitive difference. Dushtapitta can be eliminated and the raktadushti can be revised with katuki [3,4].


Manjistha, Daruharidra, Amalaki, Nimba and Harithaki all have varnya properties that guide in limiting skin staining. While treating the illness, Lekhaniyaguna of Daruharidra and Katuki is useful in lessening skin thickness and Vaivarnata. Manjistha, Daruharidra, Amalaki and Harithaki's Rasayana karma adds to a lessening in the repeat of Vicharchika. Since rasayana drugs have cancer prevention agent and immunomodulatory activities, they are used to keep up with great wellbeing. research on the previously mentioned prescriptions As indicated by Charaka, Vibhitaki can recuperate all ailments welcomed on by Rasa, Rakta and Mamsadhatudushti. This leads us to the end that it influences Rasavaha, Raktavaha and Mamsavahasrotas since they are principally engaged with or affected by the pathophysiology of Vicharchika. Nimba and Amalaki, specifically, contain Dahaprashamana properties that guide in decreasing Vicharchika's Daha condition [5,6]. These characteristics will support diminishing the pathogenesis of Vicharchika as well as the side effects of Kandu, Vaivarnata, Pidika, Rukshata, Srava, Daha and Ruja.


The clinical investigation unequivocally discovers that Durvadya Taila for outer application and LaghuManjisthadi Kwatha inside could be a solution for Vicharchika and that they can be utilized in other Kusthas too, particularly the Kaphaja-Pittaja Kusthas depicted in exemplary texts, without creating any secondary effects. Intense sickness stages have a preferable forecast over constant infection stages. Subsequently, early analysis and treatment are urgent. Long haul therapy with Durvadya Taila and Laghu ManjisthadiKwatha is expected for the all out mending of Vicharchika, particularly in constant cases.



Conflict of Interest

No conflict of interest.


  1. Kantor R, Thyssen JP, Paller AS, et al. Atopic dermatitis, atopic eczema, or eczema? A systematic review, meta‐analysis and recommendation for uniform use of ‘atopic dermatitis. Allergy. 2016;71(10):1480-5.

    Google Scholar, Crossref, Indexed at

  2. Schmitt J, Langan S, Stamm T, et al. Core outcome domains for controlled trials and clinical recordkeeping in eczema: International multiperspective Delphi consensus process. J Investig Dermatol. 2011;131(3):623-30.

    Google Scholar, Crossref, Indexed at

  3. Zink AG, Arents B, Fink-Wagner A, et al. Out-of-pocket costs for individuals with atopic eczema: A cross-sectional study in nine European countries. Acta Derm. 2019;99(3):263-7.

    Google Scholar, Crossref, Indexed at

  4. Chong M, Fonacier L. Treatment of eczema: Corticosteroids and beyond. Clin Rev Allergy Immunol. 2016 Dec;51:249-62.

    Google Scholar, Crossref, Indexed at

  5. Simpson EL. Atopic dermatitis: A review of topical treatment options. Curr Med Res Opin. 2010;26(3):633-40.

    Google Scholar, Crossref, Indexed at

  6. Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center–Community Clinical Oncology Program. J Clin Oncol. 2010;28(2):292.

    Google Scholar, Crossref, Indexed at